Table 1 Patient demographic characteristics at baseline
Variable | Monotherapy | Adjunctive therapy | |||
|---|---|---|---|---|---|
Lurasidone 20–60 mg/day (N = 161) | Lurasidone 80–120 mg/day (N = 162) | Placebo (N = 162) | Lurasidone (N = 179) | Placebo (N = 161) | |
Age, mean (SD) | 41.3 (12.3) | 42.0 (12.4) | 41.2 (12.4) | 41.0 (11.5) | 42.6 (11.8) |
Male, n (%) | 70 (43.5Â %) | 64 (39.5Â %) | 75 (46.3Â %) | 93 (52.0Â %) | 85 (52.8Â %) |
White, n (%) | 107 (66.5Â %) | 106 (65.4Â %) | 107 (66.0Â %) | 108 (60.3Â %) | 102 (63.4Â %) |
Baseline Q-LES-Q SF Percentage Maximum Score, mean (SD) | 51.3 (20.8) | 52.1 (20.0) | 45.5 (20.5) | 55.9 (19.6) | 50.4 (20.6) |
Baseline MADRS Total Score, mean (SD) | 30.3 (5.0) | 30.6 (4.9) | 30.5 (4.9) | 30.5 (5.3) | 30.7 (4.8) |